IRVINE, CA / ACCESSWIRE / March 23, 2017 / Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against HMS Holdings Corp (“HMS” or the “Company”) (NASDAQ: HMSY). Investors who purchased or otherwise acquired Babcock shares between May 10, 2015, and February 28, 2017, inclusive (the “Class Period”), are encouraged to contact the firm in advance of the May 2, 2017 lead plaintiff deadline.

If you purchased shares of HMS during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

HMS announced that it would not file its fiscal year 2016 Form 10-K on time, and that its auditor had identified what it thought was a weakness in the Company’s internal controls over fiscal reporting regarding CMS reserves. HMS stated that it is “continuing to evaluate whether this issue affects its consolidated financial results, primarily focusing on prior periods in which revenue relating to the CMS business was recorded.”

When this information was offered to the investing public, HMS stock dropped, causing investors serious harm.

If you wish to learn more about this lawsuit at no charge, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contact:

Khang & Khang LLP
Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 458051

IRVINE, CA / ACCESSWIRE / March 23, 2017 / Khang & Khang LLP (the “Firm”) announces that it is investigating claims against Trecora Resources (“Trecora” or the “Company”) (NYSE: TREC) concerning possible violations of federal securities laws.

If you purchased shares of Trecora and want more information free of charge, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

Trecora announced that the Company’s Audit Committee, “following consultation with management and discussion with the company’s independent registered public accounting firm . . . concluded that there were errors in the accounting for its equity in earnings from its investment in AMAK in Q2 and Q3 2016.” Trecora then informed shareholders that its quarterly reports for those periods should no longer be relied upon, and that it would restate its financial and operating results for those quarters before filing its 2016 annual report.

When this news was revealed to the investing public, the value of Trecora fell, causing investors serious harm.

If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contacts

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 458049

LOS ANGELES, CA / ACCESSWIRE / March 23, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Kitov Pharmaceutical Holdings Ltd., (“Kitov” or the “Company”) (NASDAQ: KTOV). Investors, who purchased or otherwise acquired Kitov shares between November 20, 2015 and February 3, 2017 inclusive (the “Class Period”), are encouraged to contact the firm in advance of the April 10, 2017 lead plaintiff deadline.

To participate in this class action lawsuit, please click here, or call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

On February 6, 2017, the Israeli publication Calcalist announced that Kitov’s Chief Executive Officer, Isaac Israel, had been held by the Israeli Securities Authority in response to allegations of publishing misleading information about a recent clinical trial of one of Kitov’s products. When this information was disclosed to the investing public, the value of Kitov stock fell, causing investors harm.

Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com

SOURCE: Lundin Law PC

ReleaseID: 458047

IRVINE, CA / ACCESSWIRE / March 23, 2017 / Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against Aetna Inc. (“Aetna” or the “Company”) (NYSE: AET) concerning possible violations of federal securities laws. Investors, who purchased or otherwise acquired shares between August 15, 2016 and January 20, 2017 inclusive (the “Class Period”), are encouraged to contact the firm in advance of the March 27, 2017 lead plaintiff motion deadline.

If you purchased shares of Aetna. during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

The Complaint alleges that during the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: Aetna and its senior executives attempted to sway Aetna’s engagement in the Public Exchanges for positive treatment from regulators in regards to the Humana acquisition; that the Company threatened to rescind its participation in public health insurance exchanges if the Department of Justice (“DOJ”) attempted to block the merger; that Aetna withdraw from some public health insurance exchanges, as per its threat of leaving the marketplace once the DOJ filed suit to improve its litigation; that Aetna withdrew from public health insurance exchanges that were profitable for Aetna; and that as a result, Defendants’ statements regarding Aetna’s business, operations, and prospects were false and misleading and/or lacked a reasonable basis. When this information was revealed to the investing public, the value of Aetna fell, causing investors harm.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

If you wish to learn more about this lawsuit, at no charge, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contact:

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 458046

TEL AVIV, ISRAEL / ACCESSWIRE / March 23, 2017 / Elbit Imaging Ltd. (TASE, NASDAQ: EMITF) (“Elbit” or the “Company”) announced today, that it was informed by Gamida Cell Ltd. (“Gamida”), an indirect associate of the Company, that the orphan drug designation, which has been granted by the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) regarding NiCord®, has been broadened and now includes any treatment which is based on blood system stem cells (haematopoetic stem cells) transplant.

The EMA grants an orphan drug designation to promote the development of products that demonstrate promise for the treatment of rare diseases. EMA Orphan drug designation provides 10 years of market exclusivity in the EU, as well as prospective grants receiving easement and assistance with developing and registration of drugs for marketing.

As of today, the development of NiCord® remains at the clinical stage of development, and there is no certainty that NiCord® will be marketed on a commercial basis.

The Company holds approximately 89.9% of the share capital of Elbit Medical Technologies Ltd. (TASE: EMTC-M) (85.8% on a fully diluted basis) which, in turn, holds approximately 25% of the share capital in Gamida (22.5% on a fully diluted basis).

About Elbit Imaging Ltd.

Elbit Imaging Ltd. operates in the following principal fields of business: (i) Commercial centers – initiation, construction, and sale of commercial centers and other mixed-use property projects, predominantly in the retail sector, located in Central and Eastern Europe. In certain circumstances and depending on market conditions, the Group operates and manages commercial centers prior to their sale; (ii) Hotel – operation and management of the Radisson hotel complex in Bucharest, Romania; (iii) Medical industries and devices – (a) research and development, production and marketing of magnetic resonance imaging guided focused ultrasound treatment equipment, and (b) development of stem cell population expansion technologies and stem cell therapy products for transplantation and regenerative medicine; (iv) Plots in India – plots designated for sale initially designated to residential projects.

Any forward-looking statements in our releases include statements regarding the intent, belief or current expectations of Elbit Imaging Ltd. and our management about our business, financial condition, results of operations, and its relationship with its employees and the condition of our properties. Words such as “believe,” “expect,” “intend,” “estimate,” and similar expressions are intended to identify forward-looking statements but are not the exclusive means of identifying such statements. Actual results may differ materially from those projected, expressed or implied in the forward-looking statements as a result of various factors including, without limitation, a change in market conditions, a decision to deploy the cash for other business opportunities and the factors set forth in our filings with the Securities and Exchange Commission including, without limitation, Item 3.D of our annual report on Form 20-F for the fiscal year ended December 31, 2015, under the caption “Risk Factors.” Any forward-looking statements contained in our releases speak only as of the date of such release, and we caution existing and prospective investors not to place undue reliance on such statements. Such forward-looking statements do not purport to be predictions of future events or circumstances, and therefore, there can be no assurance that any forward-looking statement contained in our releases will prove to be accurate. We undertake no obligation to update or revise any forward-looking statements.

For Further Information:

Company Contact

Ron Hadassi
Chairman of the Board of Directors
Tel: +972-3-608-6048
Fax: +972-3-608-6050
ron@elbitimaging.com

SOURCE: Elbit Imaging Ltd.

ReleaseID: 458040

IRVINE, CA / ACCESSWIRE / March 23, 2017 / Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against Galena Biopharma Inc. (“Galena” or the “Company”) (NASDAQ: GALE) concerning possible violations of federal securities laws. Investors, who purchased or otherwise acquired shares between August 11, 2014 and January 31, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the April 14, 2017 lead plaintiff motion deadline.

If you purchased shares of Galena during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

Galena announced plans to “divest its commercial business,” which included the Company’s innovative cancer pain drug, Abstral. On March 10, 2016, the Company disclosed that “[a] federal investigation of two of the high-prescribing physicians for Abstral has resulted in the criminal prosecution of the two physicians for alleged violations of the federal False Claims Act and other federal statutes,” and that the Company was issued a trial subpoena for documents related to that investigation. The Company also noted that “other governmental agencies may be investigating our Abstral promotion practices,” and that “on December 16, 2015, we received a subpoena issued by the U.S. Attorney’s Office in District of New Jersey requesting the production of a broad range of documents pertaining to our marketing and promotional practices for Abstral.”

On January 31, 2017, Galena announced that Mark W. Schwartz, President and Chief Executive Officer during this time, was resigning from his position.

When this information was revealed to the investing public, the value of Galena fell significantly, causing investors serious harm.

If you wish to learn more about this lawsuit, at no charge, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contact:

Joon M. Khang, Esq.

Telephone: 949-419-3834

Facsimile: 949-225-4474

joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 458044

LOS ANGELES, CA / ACCESSWIRE / March 23, 2017 / Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against AmTrust Financial Services Inc. (“AmTrust” or the “Company”) (NASDAQ: AFSI). Investors, who purchased or otherwise acquired AmTrust shares between May 10, 2016, and February 24, 2017, inclusive (the “Class Period”), are encouraged to contact the firm in advance of the May 1, 2017 lead plaintiff deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

AmTrust revealed that it “identified material weaknesses in its internal control over financial reporting that existed as of December 31, 2016, specifically related to ineffective assessment of the risks associated with the financial reporting, and an insufficient complement of corporate accounting and corporate financial reporting resources within the organization.” The Company will delay filing its 2016 annual financial statements.

When this news was released to the public, the value of AmTrust dropped, causing investors serious harm.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC

Brian Lundin, Esq.

Telephone: 888-713-1033

Facsimile: 888-713-1125

brian@lundinlawpc.com

http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 458042

IRVINE, CA / ACCESSWIRE / March 23, 2017 / Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against FXCM, Inc. (“FXCM” or the “Company”) (NASDAQ: FXCM). Investors, who purchased or otherwise acquired FXCM shares between March 15, 2012 and February 6, 2017, inclusive (the “Class Period”), are encouraged to contact the firm in advance of the April 10, 2017 lead plaintiff deadline.

If you purchased shares of FXCM during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

On February 6, 2017, the U.S. Commodity Futures Trading Commission stopped FXCM from operating in the U.S. When this news was announced to the investing public, the value of FXCM stock fell, causing investors serious harm.

If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contact:

Joon M. Khang, Esq.

Telephone: 949-419-3834

Facsimile: 949-225-4474

joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 458041

IRVINE, CA / ACCESSWIRE / March 23, 2017 / Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against Natus Medical Incorporated (“Natus” or the “Company”) (NASDAQ: BABY). Investors, who purchased or otherwise acquired Natus shares between October 16, 2015 and April 3, 2016, inclusive (the “Class Period”), are encouraged to contact the firm in advance of the March 31, 2017 lead plaintiff motion deadline.

If you purchased shares of Natus during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

The Complaint states that throughout the Class Period, Natus issued materially false and/or misleading statements, as well as failed to disclose material adverse facts about its business, operations, and prospects, including that: the government of Venezuela could not render tens of millions of dollars in prepayments to Natus, required in October 2015; that Natus did not hold the means to effectively enforce its rights under its supply contract; Natus’ revenues related to the supply contract were dependent on the outcome of Venezuelan elections; and therefore, Natus could not effectively achieve the increased guidance offered by Defendants, which lacked a reasonable basis. When this information was disclosed to the public, the value of Natus Medical Incorporated fell, causing investors serious harm.

If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contact:

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 458031